Oxford Nanopore
Oxford Nanopore Technologies was founded in 2005 to develop an electronic, single molecule sensing system based on nanopore science. The company now has more than 250 employees from multiple disciplines including nanopore science, molecular biology and applications, informatics, engineering, electronics, manufacturing and commercialization. Oxford Nanopore's instruments â MinIon, PromethIon, and GridIon are adaptable for the analysis of DNA, RNA, proteins, small molecules and other types of molecule.
Oxford Nanopore Facts
CEO: Gordon Sanghera
Website: www.nanoporetech.com
Ticker symbol: Privately held
Headquarters: Oxford, UK
Number of employees: 250+
The company’s research-use-only AmplideX Nanopore Carrier Plus kit can interrogate 11 genes underpinning nine common carrier screening conditions.
The company plans to release Ampore-TB for research use only later this year, followed by regulatory submissions in the US and Europe.
WHO Publishes New Guidance Recommending Targeted NGS for Drug-Resistant TB Diagnosis
The WHO specifically highlighted targeted sequencing assays from Genoscreen, Oxford Nanopore Diagnostics, and Hangzhou ShengTing Medical Technology.
Top Five Articles on 360Dx Last Week: Talis Biomedical Layoffs; PAMA Implementation Delay; More
Last week, readers were most interested in a story about layoffs at Talis Biomedical as the company plans to explore strategic alternatives.
Oxford Nanopore, Norwegian Centre for Clinical Cancer Research Ink Collaboration
The collaboration will focus on central nervous system tumors and be conducted at Oslo University Hospital using Oxford Nanopore's PromethIon 24 device.